BioSpace News Archive

Growing requirement in surgeries along with increasing application of lidocaine in dental procedures are the major factor influencing market growth.

ScreenPro Security Inc. (CSE: SCRN) (“ScreenPro” or the “Company”) is pleased to provide an update on COVID-19 testing numbers for the month of June. The Company provided services to production companies in Toronto and Vancouver and completed approximately 18,500 tests in June.

Increasing prevalence of cancer, diabetes and cardiovascular diseases along with increasing adoption of high-content screening techniques.

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx™ HAdV Quant Assay for the identification and quantification of human adenovirus (HAdV) DNA has received CE-IVD certification for the European Union and other countries that accept this marking.

Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid™ COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant.

Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company developing Resolvin-based therapies, announced today the launch of a new program in cancer and the formation of a scientific advisory board (SAB) with several prominent cancer researchers and industry veterans.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing on July 7, 2021 of its initial public offering in the United States

Cyclerion Therapeutics, Inc. and Beacon Biosignals announced an extended and expanded strategic partnership between the two companies.

Ovid Therapeutics Inc. (NASDAQ: OVID) today announced appointments to its board of directors and leadership team as well as a realignment of its workforce to focus on early-stage development activities, including the build out of its neuroscience programs